---
type: "WebPage"
title: "ADC Sequencing Services Laboratory (Antibody-Drug Conjugates)"
description: "ADC Sequencing: validating the Structure of your complex molecules Antibody-Drug Conjugates (ADCs) are complex hybrid molecules that combine the specificity of a monoclonal antibody (mAb) with the potency of a cytotoxic agent (payload) via a chemical linker. FILAB supports biopharmaceutical..."
resource: "https://filab.fr/en/sectors-of-activity/biopharmaceutical/adc-sequencing-services-laboratory-antibody-drug-conjugate/"
tags: ["EN", "Anaïs DECAUX"]
timestamp: "2026-02-27T08:30:56Z"
published: "2026-02-18T08:29:45Z"
language: "en"
author: "Filab"
---

# ADC Sequencing Services Laboratory (Antibody-Drug Conjugates)

## ADC Sequencing: validating the Structure of your complex molecules

**Antibody-Drug Conjugates (ADCs)** are complex hybrid molecules that combine the specificity of a [monoclonal antibody (mAb)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-monoclonal-antibodies-mabs.md) with the potency of a cytotoxic agent (payload) via a chemical linker.

**FILAB**supports biopharmaceutical developers in the complete sequencing and structural verification of their ADCs, using state-of-the-art[High-Resolution Mass Spectrometry (HRMS)](https://filab.fr/en/our-technical-resources/high-resolution-mass-spectrometry-hrms-analysis.md) technologies. 

### Our sequencing and structural characterization services:

  services
## ADC Sequencing

 To guarantee the identity and integrity of your Antibody-Drug Conjugates, the FILAB laboratory deploys a multi-technique approach:
Amino Acid Sequencing **[(De Novo Sequencing)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/de-novo-protein-sequencing.md)**

**[Peptide Mapping](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/peptide-analysis-biopharmaceutical-services.md)**

Post-Translational Modification (PTM)

## Our technical resources:

 To perform these high-precision sequencing tasks, FILAB relies on a 5200 m² analytical facility dedicated to fine characterization: [### High-Resolution Mass Spectrometry (HRMS)](https://filab.fr/en/our-technical-resources/high-resolution-mass-spectrometry-hrms-analysis.md) [### Orbitrap](https://filab.fr/en/our-technical-resources/lc-orbitrap-analysis.md) [### QTOF](https://filab.fr/en/our-technical-resources/laboratory-for-lc-qtof-analysis.md)   Discover our case study
## ADC Analysis: key questions & answers

 [Learn more](https://filab.fr/en/adc-analysis-services-expert-qa-filab-laboratory.md)
### Why choose FILAB ?

- **Tailor-Made Support:** from preclinical phases (R&D) to clinical batch control.
- **Dual competence:** Chemistry / Materials
- **Quality context:** services available under ISO 17025 accreditation and GMP (Good Manufacturing Practice) context.
- **Problem solving:** we don't just deliver spectra; we provide a complete interpretation of your drug candidate's structure.

## Our FAQ

 What is the difference between sequencing a standard mAb and an ADC?
Sequencing an ADC is more complex because the grafted cytotoxic agents can mask certain enzymatic cleavage sites or alter the mass spectrum. At **FILAB**, we use specific protocols (sometimes including a deconjugation step) to "clean" the signal and ensure maximum sequence coverage of the carrier antibody.

 Can you precisely locate where the drug is attached (Drug Load Distribution)?
Yes. Through [LC-MS/MS](https://filab.fr/en/our-technical-resources/laboratory-analysis-uplc/laboratory-analysis-hplc-lcms.md) [Peptide Mapping](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/peptide-analysis-biopharmaceutical-services.md), we can identify peptides modified by the linker-drug and thus determine the conjugation sites (Cysteine, Lysine, or site-specific). This also allows us to corroborate the Drug-to-Antibody Ratio (DAR) calculation.

 Do you need the theoretical sequence to work?
It is preferable for sequence confirmation ([Peptide Mapping](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/peptide-analysis-biopharmaceutical-services.md)), as it accelerates data processing. However, thanks to our [De Novo sequencing](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/de-novo-protein-sequencing.md) capabilities by mass spectrometry, we can determine the amino acid sequence even without complete prior information.

 What sample volume is required?
Mass spectrometry techniques are highly sensitive. Generally, a few hundred micrograms (µg) of ADC are sufficient for a complete sequencing and mapping study. Contact our team to validate the quantity based on your concentration.

 How to get a quote with FILAB?
To get a quote, you can contact our team via our [contact form](https://filab.fr/en/contact-form.md), by phone, or by email.
Simply send us your requirements (material type, desired analysis, specific standards, urgency, number of samples, etc.). We will then send you a personalized technical and price proposal within **24 to 48 hours**.

 What is the typical turnaround time for analysis?
Turnaround times vary depending on the nature of the analysis and the complexity of the project.
However, FILAB is committed to providing fast results tailored to your industrial constraints and urgent needs.